Cetus Corp said European Patent Office allowed intends grant company patent pharmaceutical veterinary preparation genetically engineered Interleukin-2 analog .
Interleuken-2 immune modulating protein currently undergoing clinical trial United States Europe potential use treatment various form cancer , Cetus said .
It said allowance first step patent process .
Following allowance , patent published opposition nine-month period begin interested party opportunity voice objection patent , Cetus said .
Reuter & # 3 ; 